For Immediate Release
Corgenix to Exhibit AspirinWorks® Test at Pri-Med New York
Test measures urinary 11dhTxB2 to assess aspirin effect
DENVER— June 15, 2010 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks® Test June 17-19 at the Pri-Med New York 2010 conference. The meeting will take place at the Jacob K. Javits Convention Center in New York, N.Y.
Corgenix representatives will be on-hand during the conference at booth No. 700 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information. Complimentary AspirinWorks Tests will be offered to qualified attendees during regular exhibit hours June 17-19. Test results will be provided after the conference.
The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.
The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest, LabCorp, SpectraCell and Health Diagnostic Laboratory, Inc. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be
obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.
Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email email@example.com. More information is also available at www.aspirinworks.com.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230